Kedrion Biophar Patent-Cliff Exposure & CMS Drug Spending Portfolio

Kedrion Biophar (US): 8 reconciled FDA prescription therapies, $316.9M 2024 CMS Part D & Medicaid spend, and 18 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies8
2025 to 2030 Patent-Cliff Revenue Exposure0.0%
Primary Portfolio LOE DateMulti-asset schedule
2024 CMS Total Public Spend$316.9M
2024 Medicare Part D Spend$270.1M
2024 Medicaid Spend$46.8M
California HCAI SB 17 Filings18 WAC filings (max 371.1% 2-yr change)